Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Masaharu Ishikawa is active.

Publication


Featured researches published by Masaharu Ishikawa.


Journal of Immunology | 2008

Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats

Tomonori Tawara; Kazumasa Hasegawa; Yusuke Sugiura; Katsuhiko Harada; Toru Miura; Sunao Hayashi; Tomoyuki Tahara; Masaharu Ishikawa; Hideaki Yoshida; Kinya Kubo; Isao Ishida; Shiro Kataoka

Infusion reactions are a major side effect of the administration of therapeutic Abs and are the result of a complex immune reaction. In this study, we report that substitutions of Fc amino acids in the anti-HLA-DR Ab HD8 reduce its ability to induce infusion reactions in rats and monkeys. We first showed that i.v. administration of IgG1- and IgG2-subclass HD8 Abs induces severe infusion reactions in monkeys. These Abs express strong complement-dependent cytotoxicity (CDC), and in vivo depletion of complement in rats by pretreatment with cobra venom factor abrogated the lethal infusion reactions generated by HD8-IgG1. Thus, the infusion reactions appear to be largely driven by the complement system. To reduce the CDC function of HD8-IgG1, its Fc region was modified by two amino acid substitutions at Pro331Ser and Lys322Ala. The modified Ab was incapable of expressing CDC in vitro and did not induce severe infusion reactions in rats and monkeys, even at extremely high doses. The modified Ab retained its Ab-dependent cellular cytotoxicity function as well as its antitumor activity in a tumor-bearing mouse model. In summary, complement appears to drive infusion reactions, and modifications that eliminate the CDC activity of an Ab also reduce its ability to induce infusion reactions.


Analytical Biochemistry | 1991

Mutant protein of recombinant human granulocyte colony-stimulating factor for receptor binding assay

Masahiko Watanabe; Hiromi Fukamachi; Hiroya Uzumaki; Koji Kabaya; Haruhiko Tsumura; Masaharu Ishikawa; Shigeru Matsuki; Masaru Kusaka

A new mutant protein of recombinant human granulocyte colony-stimulating factor (rhG-CSF) was produced for the studies on receptors for human G-CSF. The mutant protein [(Tyr1, Tyr3]rhG-CSF), the biological activity of which was almost equal to that of rhG-CSF, was prepared by the replacement of threonine-1 and leucine-3 of rhG-CSF with tyrosine. The radioiodinated preparation of the mutant protein showed high specific radioactivity and retained full biological activity for at least 3 weeks. The binding capacity of the radioiodinated ligand was compared with that of [35S]rhG-CSF. Both radiolabeled ligands showed specific binding to murine bone marrow cells. Unlabeled rhG-CSF and human G-CSF purified from the culture supernatant of the human bladder carcinoma cell line 5637 equally competed for the binding of labeled rhG-CSFs in a dose-dependent manner, demonstrating that the sugar moiety of human G-CSF made no contribution to the binding of human G-CSF to target cells. In contrast, all other colony-stimulating factors and lymphokines examined did not affect the binding. Scatchard analysis of the specific binding of both labeled ligands revealed a single class of binding site with an apparent dissociation constant (Kd) of 20-30 pM and 100-200 maximal binding sites per cell. These data indicate that the radioiodinated preparation of the mutant protein binds the same specific receptor with the same affinity as [35S]rhG-CSF. The labeled mutant protein also showed specific binding to human circulating neutrophils.(ABSTRACT TRUNCATED AT 250 WORDS)


International Archives of Allergy and Immunology | 1999

Effect of interleukin-3, interleukin 5 and hyaluronic acid on cultured eosinophils derived from human umbilical cord blood mononuclear cells.

Hiroshi Ohashi; Masao Takei; Youichi Ide; Hiromi Ishii; Hirohito Kita; Gerald J. Gleich; Masaharu Ishikawa; Hiromi Fukamachi

Background: Several studies have shown that cultured eosinophils can be generated from human umbilical cord blood mononuclear cells (UCMC) in the presence of interleukin (IL)–3 and IL–5 in vitro. Other reports have indicated that cellular adhesion to hyaluronic acid (HA) enhances the proliferation of cultured eosinophils derived from CD34+ cells purified from UCMC. The aim of this study was to obtain large numbers of mature eosinophils from UCMC using IL–3, IL–5 and HA, and to investigate their functions. Methods: We examined several combinations of IL–3 and IL–5 and their effect on eosinophil development from UCMC in HA–coated on non–coated flasks. We also examined whether cultured eosinophils degranulated eosinophil–derived neurotoxin (EDN) induced by secretory immunoglobulin A conjugated to sepharose beads (sIgA–beads) and responded to eotaxin. Results: Culture with HA–coated flasks for 35 days (in the presence of IL–3 and IL–5, with IL–3 omitted after day 14 of culture) caused a 11.2–fold augmentation in the proliferation of UCMC. On day 35 of the culture, 98% of cultured cells were eosinophils judging from May–Grünwald and Giemsa staining and transmission electron micrographs. The EDN content of the cultured eosinophils on day 35 was 156 ng/105 cells. Cultured eosinophils degranulated EDN induced by sIgA–beads and responded to eotaxin by chemotaxis and intracellular Ca2+ mobilization. Conclusion: We found a useful culture system to obtain large numbers of eosinophils derived from UCMC, which may facilitate the investigation of eosinophil function, since there was no significant difference in response to sIgA–beads and eotaxin between cultured and peripheral eosinophils.


General Pharmacology-the Vascular System | 1994

Pharmacological effects of recombinant human granulocyte colony-stimulating factor modified by polyethylene glycol on anticancer drug-induced neutropenia in mice

Masaharu Ishikawa; Yuji Okada; Rika Satake-Ishikawa; Makoto Kakitani; Mayumi Kawagishi; Shigeru Matsuki; Masaru Kusaka; Katsuhiko Asano

1. To clarify the pharmacological effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) conjugated to polyethylene glycol (PEG), its effects on the number of circulating neutrophils in mice made neutropenic by cyclophosphamide (CPA) or 5-fluorouracil (5-FU) were compared with rhG-CSF lacking PEG. 2. In normal mice, PEG-conjugated rhG-CSF (PEG-rhG-CSF, 10 micrograms protein/kg) induced an increase in neutrophils which lasted for 72 h after injection whereas the effect of rhG-CSF (10 micrograms protein/kg) disappeared by 24 h after injection. 3. In CPA or 5-FU-induced neutropenic mice, PEG-rhG-CSF inhibited neutropenia or accelerated recovery from neutropenia and its potency was higher than that of rhG-CSF. 4. These results indicate that PEG-rhG-CSF has a longer duration of action than rhG-CSF and is more effective in the recovery from neutropenia.


Bioorganic & Medicinal Chemistry Letters | 1999

Effects of ortho-substituent groups of sulochrin on inhibitory activity to eosinophil degranulation.

Hiroshi Ohashi; Akihiro Ueno; Toyoo Nakao; Junko Ito; Kaname Kimura; Masaharu Ishikawa; Hiroyuki Kawai; Hiroshi Iijima; Tatsushi Osawa

Sulochrin, a metabolite of fungi, has been shown to have an inhibitory activity to eosinophil degranulation. A series of sulochrin derivatives substituted at ortho-positions to the 10-carbonyl group was examined the activity. The importance of alkylester at C-6 position and several chemical properties of substituted groups at ortho-positions to exhibit activity are described.


Biotechnology Letters | 1993

Protein tailoring of human granulocyte colony-stimulating factor

Masaharu Ishikawa; Yuji Okada; Rika Ishikawa; Haruhiko Tsumura; Shigeru Matsuki; Katsuhiko Asano

SummaryRecombinant human granulocyte-colony stimulating factor (rhG-CSF) was modified by site-directed mutagenesis and chemical modification in order to improve its pharmacological activity and its thermostability. The mutant rhG CSF which 17th cysteine was substituted with alanine was chemically modified by activated polyethylene glycol. The chemically modified mutant rhG-CSF greatly increased both its biological activityin vivo and its thermostability. This is a successful example of protein tailoring in which site-directed mutagenesis and chemical modification were used at the same time.


Cancer Research | 1991

Pharmacokinetics of Recombinant Human Granulocyte Colony-stimulating Factor Conjugated to Polyethylene Glycol in Rats

Hideji Tanaka; Rika Satake-Ishikawa; Masaharu Ishikawa; Shigeru Matsuki; Katsuhiko Asano


Journal of Immunology | 1994

Identification of a protein, SPY75, with repetitive helix-turn-helix motifs and an SH3 domain as a major substrate for protein tyrosine kinase(s) activated by Fc epsilon RI cross-linking.

Hiromi Fukamachi; Nobuo Yamada; Toru Miura; Takashi Kato; Masaharu Ishikawa; Erich Gulbins; Amnon Altman; Yuko Kawakami; Toshiaki Kawakami


Cell Structure and Function | 1992

Chemical Modification of Recombinant Human Granulocyte Colony-Stimulating Factor by Polyethylene Glycol Increases its Biological Activity in vivo

Rika Satake-Ishikawa; Masaharu Ishikawa; Yuji Okada; Makoto Kakitani; Mayumi Kawagishi; Shigeru Matsuki; Katsuhiko Asano


Cell Structure and Function | 1992

The substitution of cysteine 17 of recombinant human G-CSF with alanine greatly enhanced its stability.

Masaharu Ishikawa; Hiroshi Iijima; Rika Satake-Ishikawa; Haruhiko Tsumura; Akihiro Iwamatsu; Toshihiko Kadoya; Yoshihiro Shimada; Hiromi Fukamachi; Keiko Kobayashi; Shigeru Matsuki; Katsuhiko Asano

Collaboration


Dive into the Masaharu Ishikawa's collaboration.

Top Co-Authors

Avatar

Hiromi Fukamachi

La Jolla Institute for Allergy and Immunology

View shared research outputs
Top Co-Authors

Avatar

Hiroshi Ohashi

Nara Institute of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Akihiro Ueno

Nara Institute of Science and Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge